Category Archives: Regulatory

Biosimilar Development in Europe: Ten Years On

The European Union established the first legal regulatory guidelines for biosimilars in 2005. The first biosimilar, Omnitrope, a version of somatropin, was approved in April 2006. To date, the EU has approved 19 applications in total (two were withdrawn after authorization so 17 are now marketed) and continues to update its guidelines, general and product-specific, […]
Also posted in Biotech, Europe | Tagged , | Leave a comment

EMA Invites Comments on Good Biomarker Practice

The European Medicines Agency (EMA) has released a consultation on good genomics biomarker practices. The outcome of the consultation will inform a guideline, which will set criteria to underpin the generation of robust clinical genomic datasets throughout a medicine’s lifecycle,  the choice of genomic techniques and biomarkers, the impact on the relevant study design, and the […]
Also posted in Biotech, Europe, Global | Tagged , , | Leave a comment

EMA Invites Comments on Guidance for Flu Vaccines

The European Medicines Agency (EMA) has released the second module of a new overarching guideline on influenza vaccines for a six-month public consultation. The guidance covers the non-clinical and clinical requirements for the development of new influenza vaccines and aims to facilitate the prompt assessment of new vaccines. It follows the publication in April of […]
Also posted in Europe, Global | Tagged , | Leave a comment

FDA Announces Diagnostic Testing Measures

FDA has announced it is taking steps to ensure that certain diagnostic tests are accurate, consistent and reliable. The Agency is first issuing a final guidance on the development, review and approval or clearance of companion diagnostics, which are commonly used to detect certain types of gene-based cancers. Second, it will publish a risk-based oversight […]
Also posted in FDA, Gene therapy, Safety | Tagged , , | Leave a comment

The European Parliament’s New Term: What Can We Expect?

As Europe departs for its annual holiday—sacrosanct, even amid the continuing economic woes, the multiple crises in the Middle East, and the dark mysteries of Russia’s intentions in its former satellites—the question remains unresolved as to what to expect from the new European Parliament in the new term. Philip Ward considers the options in this […]
Also posted in Europe, Global, Guest Blog | Tagged , , | Leave a comment
  • Categories

  • Meta